Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 May 17:2011:bar017.
doi: 10.1093/database/bar017. Print 2011.

hERGAPDbase: a database documenting hERG channel inhibitory potentials and APD-prolongation activities of chemical compounds

Affiliations

hERGAPDbase: a database documenting hERG channel inhibitory potentials and APD-prolongation activities of chemical compounds

Haretsugu Hishigaki et al. Database (Oxford). .

Abstract

Drug-induced QT interval prolongation is one of the most common reasons for the withdrawal of drugs from the market. In the past decade, at least nine drugs, i.e. terfenadine, astemizole, grepafloxacin, terodiline, droperidol, lidoflazine, sertindole, levomethadyl and cisapride, have been removed from the market or their use has been severely restricted because of drug-induced QT interval prolongation. Therefore, this irregularity is a major safety concern in the case of drugs submitted for regulatory approval. The most common mechanism of drug-induced QT interval prolongation may be drug-related inhibition of the human ether-á-go-go-related gene (hERG) channel, which subsequently results in prolongation of the cardiac action potential duration (APD). hERGAPDbase is a database of electrophysiological experimental data documenting potential hERG channel inhibitory actions and the APD-prolongation activities of chemical compounds. All data entries are manually collected from scientific papers and curated by a person. With hERGAPDbase, we aim to provide useful information for chemical and pharmacological scientists and enable easy access to electrophysiological experimental data on chemical compounds. Database URL: http://www.grt.kyushu-u.ac.jp/hergapdbase/.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Overall method for hERGAPDbase data collection. (A) Two types of papers related to the hERG assay and the APD assay found in PubMed. (B) hERG assay data and APD assay data were extracted manually from scientific papers. The structural data of the chemical compounds (SDF; SMILES; and JPEG files) were obtained from PubChem.
Figure 2.
Figure 2.
Schematic representation of hERGAPDbase architecture. hERGAPDbase consists of five data tables: PubMed data, Chemical compound data, FP DB, APD assay data and HERG assay data. The abbreviations APD and HERG indicate APD and hERG, respectively. The PubMed data table consists of two attributes: PubMed Unique Identifier (PMID) and Link to Abstract. The Chemical compound data table consists of five attributes: chemical name, Sybyl Mol2 chemical modeller output (MOL2), SDF, SMILES and JPEG). The FP DB data table consists of two attributes: chemical name and FP. The APD assay data table consists of 11 attributes: PMID, chemical name, concentration, species, tissues, cell, measure after perfusion, stimulation, APD at 30% repolarization (APD30), APD at 60% repolarization (APD60) and APD at 90% repolarization (APD90). The HERG assay data table consists of seven attributes: PMID, chemical name, half maximal inhibitory concentration (IC50; µM), species, host cell, HERG channel expression system and experimental temperature.
Figure 3.
Figure 3.
Overall outline of hERGAPDbase. (A) Homepage of hERGAPDbase. (B) Screen capture of the similarity search homepage for query input. In this example, astemizole is specified in the pull-down menu. (C) The resulting table from the similarity search in the FP DB of the hERGAPDbase. (D) Table of the hERG assay data for astemizole in this example. (E) Table of the APD assay data for astemizole. (F) Platform of data download for SDF, SMILES and JPEG files. (G) Paper abstracts of data resources for the hERG and APD assays from PubMed.
Figure 4.
Figure 4.
Screen capture of the similarity search results for astemizole. The attributes listed in the results table, i.e. No., chemical name, structure, score, hERG channel assay results and APD assay results, indicate the compound's similarity rank among the top 30 compounds, the name of the chemical compounds, JPG images of the chemical compounds, the similarity score calculated by tanimoto.pl, hERG assay results and the APD assay results, respectively.
Figure 5.
Figure 5.
Screen capture of the hERG assay results for astemizole. (A) Example of hERG assay result using hERG channel stably expressed on HEK 293 cells. (B) Example of hERG assay result using a hERG channel transiently expressed in a Xenopus oocyte. The attributes listed in the results table, i.e. chemical name, IC50 (µM), species, host cell and PMID, indicate the name of the chemical compounds, the half maximal inhibitory concentration of the hERG channel, the origin of the hERG channel, cell with natural and/or artificial expression of hERG channel and PMID, respectively.
Figure 6.
Figure 6.
Screen capture of the APD assay results for astemizole. (A) Example of APD in the case of 0.1 μmol/l concentration. (B) Example of APD in the case of 10.0 μmol/l concentration. The attributes listed in the results table, i.e. chemical name, concentration (µM), species, tissue, cell, measure after perfuse (min), stimulation (Hz), APD30, APD60, APD90 and PMID, indicate the name of the chemical compounds, concentration of the chemical compounds and/or drugs for measurement of the action potential, origin of tissues and cells tested for the action potential of the compounds, tissues for extracting cells, cells extracted from tissues for measuring the action potential, time measurement of the action potential after perfusion of compounds, electrical stimulation frequency for the preparation, APD at 30% repolarization, APD at 60% repolarization, APD at 90% repolarization and PMID, respectively.

Similar articles

Cited by

References

    1. Yap YG, Camm AG. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89:1363–1372. - PMC - PubMed
    1. Friedrichs GS, Patmore L, Bass A. Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies. J. Pharmacol. Toxicol. Methods. 2005;52:6–11. - PubMed
    1. Kang J, Wang L, Chen XL, et al. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol. Pharmacol. 2001;59:122–126. - PubMed
    1. Bowlby MR, Peri R, Zhang H, et al. hERG (KCNH2 or Kv11.1) K+ channels: Screening for cardiac arrhythmia risk. Curr. Drug Metab. 2008;9:965–970. - PubMed
    1. Ando K. Drug-induced QT prolongation: individual susceptibility and regulatory issues related to safety pharmacology 2. Evaluation of QT interval prolongation in non-clinical studies according to ICH S7A and S7B and its questions at issue. Jpn. J. Clin. Pharmacol. Ther. 2006;37:201–206.

Publication types

Substances